[go: up one dir, main page]

PE20170301A1 - Medios y metodos para el tratamiento cmv - Google Patents

Medios y metodos para el tratamiento cmv

Info

Publication number
PE20170301A1
PE20170301A1 PE2016002191A PE2016002191A PE20170301A1 PE 20170301 A1 PE20170301 A1 PE 20170301A1 PE 2016002191 A PE2016002191 A PE 2016002191A PE 2016002191 A PE2016002191 A PE 2016002191A PE 20170301 A1 PE20170301 A1 PE 20170301A1
Authority
PE
Peru
Prior art keywords
cmv
methods
expression
refers
proteins
Prior art date
Application number
PE2016002191A
Other languages
English (en)
Inventor
Corinne John
Sabine Wellnitz
Christian Schaub
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20170301A1 publication Critical patent/PE20170301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a un complejo pentamerico compuesto de proteinas CMV UL128, UL130, UL131A, gH (UL75) y gL (UL115) obtenibles por el metodo que comprende en (i) co-expresion de dichas proteinas en una celula hospedera mediante el uso de baculovirus; (ii) purificar el complejo pentamerico de las celulas hospederas y/o sobrenadante de acogida obtenidos a partir de dicha co-expresion; y (iii) almacenar opcionalmente dicho complejo en una solucion tampon que comprende un agente quelante y/o estabilizante. Tambien se refiere a una composicion de vacuna que lo comprende, siendo util en el tratamiento contra el citomegalovirus (CMV)
PE2016002191A 2014-05-08 2015-05-08 Medios y metodos para el tratamiento cmv PE20170301A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
LU92449 2014-05-08
LU92450 2014-05-08
LU92452 2014-05-08
LU92451 2014-05-08

Publications (1)

Publication Number Publication Date
PE20170301A1 true PE20170301A1 (es) 2017-03-30

Family

ID=53180768

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002191A PE20170301A1 (es) 2014-05-08 2015-05-08 Medios y metodos para el tratamiento cmv

Country Status (16)

Country Link
US (1) US20150322115A1 (es)
EP (1) EP3139953A1 (es)
JP (1) JP2017515503A (es)
KR (1) KR20170002560A (es)
CN (1) CN106460010A (es)
AU (1) AU2015257330A1 (es)
BR (1) BR112016025792A2 (es)
CA (1) CA2947938A1 (es)
IL (1) IL248803A0 (es)
MX (1) MX2016014660A (es)
PE (1) PE20170301A1 (es)
PH (1) PH12016502220A1 (es)
RU (1) RU2016147987A (es)
SG (1) SG11201608977UA (es)
TW (1) TW201609792A (es)
WO (1) WO2015170287A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
US20230248820A1 (en) 2017-04-19 2023-08-10 Glaxosmithkline Biologicals, S.A. Modified cytomegalovirus proteins and stabilized complexes
SG11202002174SA (en) 2017-09-13 2020-04-29 Sanofi Pasteur Human cytomegalovirus immunogenic composition
BR112020008482A8 (pt) * 2017-11-01 2023-01-31 Merck Sharp & Dohme Composto leuco
CN108300731A (zh) * 2018-02-02 2018-07-20 暨南大学 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用
KR200492821Y1 (ko) 2018-08-10 2020-12-15 인제대학교 산학협력단 의료용 튜브 고정 기구
EP3866845A1 (en) 2018-10-17 2021-08-25 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
AU2019397719B2 (en) * 2018-12-10 2023-11-09 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
AU2021287508B2 (en) 2020-06-09 2023-11-09 Km Biologics Co., Ltd. Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
KR102259156B1 (ko) 2020-09-28 2021-06-01 박나은 네트워크 환경 내 디바이스 인증 시스템 및 방법
AU2021367917A1 (en) 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
US20250325656A1 (en) 2022-05-20 2025-10-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins
CN117257925B (zh) * 2023-09-20 2024-05-28 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
EP1242576B1 (en) * 1999-12-14 2005-04-13 Thermo Biostar, Inc. Stabilizing diluent for polypeptides and antigens
US7629160B2 (en) 2004-12-21 2009-12-08 University Of Kentucky Research Foundation Vectors and methods for enhanced cell longevity and protein expression
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
KR102162111B1 (ko) * 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
KR20140007404A (ko) * 2011-01-31 2014-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법
JP2014520807A (ja) * 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
CA2878344A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
KR20150076244A (ko) * 2012-10-30 2015-07-06 레드박스 게엠베하 인간 시토메갈로바이러스 감염에 대한 재조합 입자 기재 백신

Also Published As

Publication number Publication date
TW201609792A (zh) 2016-03-16
US20150322115A1 (en) 2015-11-12
CN106460010A (zh) 2017-02-22
RU2016147987A (ru) 2018-06-13
IL248803A0 (en) 2017-01-31
MX2016014660A (es) 2017-02-28
PH12016502220A1 (en) 2017-01-09
JP2017515503A (ja) 2017-06-15
SG11201608977UA (en) 2016-11-29
AU2015257330A1 (en) 2016-11-17
CA2947938A1 (en) 2015-11-12
WO2015170287A1 (en) 2015-11-12
EP3139953A1 (en) 2017-03-15
KR20170002560A (ko) 2017-01-06
BR112016025792A2 (pt) 2017-10-17

Similar Documents

Publication Publication Date Title
PE20170301A1 (es) Medios y metodos para el tratamiento cmv
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
PH12018500855A1 (en) Herpes simplex virus vaccine
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
CL2015002709A1 (es) Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
CO2018012513A2 (es) Anticuerpos
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
MX2016013767A (es) Anticuerpos humanizados contra cd269 (bcma).
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
MX2018002315A (es) Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
EA201790069A1 (ru) Дифторметилникотиновые инданилкарбоксамиды
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112016029178A2 (pt) composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX378747B (es) Complejos de proteínas de citomegalovirus.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
EP3224712A4 (en) Support for application transparent, high available gpu computing with vm checkpointing
AR086871A1 (es) Composicion descongelante, proceso de preparacion, conjunto de partes y uso
MX381290B (es) Formulaciones de peróxido y métodos y aplicaciones para utilizarlas.
EA201790461A1 (ru) Композиции внеклеточного матрикса

Legal Events

Date Code Title Description
FD Application declared void or lapsed